These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 19372840)

  • 1. Evaluation and management of early virological failure.
    Sax PE
    Curr Opin HIV AIDS; 2006 Sep; 1(5):409-16. PubMed ID: 19372840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on HIV-1 viral load blips.
    Nettles RE; Kieffer TL
    Curr Opin HIV AIDS; 2006 Mar; 1(2):157-61. PubMed ID: 19372801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variable adherence to prescribed dosing regimens for protease inhibitors: scope and outcomes.
    Blaschke TF
    Curr Opin HIV AIDS; 2008 Nov; 3(6):603-7. PubMed ID: 19373030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice.
    Fabbiani M; Di Giambenedetto S; Bracciale L; Bacarelli A; Ragazzoni E; Cauda R; Navarra P; De Luca A
    J Antimicrob Chemother; 2009 Jul; 64(1):109-17. PubMed ID: 19398461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
    Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
    AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on HIV-1 antiretroviral resistance.
    Plank RM; Kuritzkes DR
    Curr Opin HIV AIDS; 2006 Sep; 1(5):417-23. PubMed ID: 19372841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy.
    Wang D; Larder B; Revell A; Montaner J; Harrigan R; De Wolf F; Lange J; Wegner S; Ruiz L; Pérez-Elías MJ; Emery S; Gatell J; D'Arminio Monforte A; Torti C; Zazzi M; Lane C
    Artif Intell Med; 2009 Sep; 47(1):63-74. PubMed ID: 19524413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvements in antiretroviral therapy outcomes over calendar time.
    Boyd MA
    Curr Opin HIV AIDS; 2009 May; 4(3):194-9. PubMed ID: 19532050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral fitness: relation to drug resistance mutations and mechanisms involved: nucleoside reverse transcriptase inhibitor mutations.
    Weber J; Henry KR; Arts EJ; Quiñones-Mateu ME
    Curr Opin HIV AIDS; 2007 Mar; 2(2):81-7. PubMed ID: 19372871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment.
    Roux P; Carrieri MP; Cohen J; Ravaux I; Poizot-Martin I; Dellamonica P; Spire B
    Clin Infect Dis; 2009 Nov; 49(9):1433-40. PubMed ID: 19807275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.
    Kandathil AJ; Kannangai R; Verghese VP; Pulimood SA; Rupali P; Sridharan G; Grant P; Pillay D; Abraham OC
    Indian J Med Microbiol; 2009; 27(3):231-6. PubMed ID: 19584504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initiation of antiretroviral therapy.
    Pozniak A
    Curr Opin HIV AIDS; 2006 Sep; 1(5):398-408. PubMed ID: 19372839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Issues in the design of trials comparing management strategies for heavily pretreated patients.
    Phillips AN; Cohen C; Lundgren JD
    Curr Opin HIV AIDS; 2006 Nov; 1(6):476-81. PubMed ID: 19372849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy.
    Di Giambenedetto S; Zazzi M; Corsi P; Gonnelli A; Di Pietro M; Giacometti A; Almi P; Trezzi M; Boeri E; Gianotti N; Menzo S; Del Gobbo R; Francisci D; Nerli A; Galli L; De Luca A;
    Antivir Ther; 2009; 14(3):359-69. PubMed ID: 19474470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of selecting resistance mutations during treatment interruption.
    Martinez-Picado J; Wai Yan Tam L
    Curr Opin HIV AIDS; 2007 Jan; 2(1):6-13. PubMed ID: 19372859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological responses during a virologically failing antiretroviral regimen are associated with in vivo synonymous mutation rates of HIV type-1 env.
    Mens H; Jørgensen LB; Kronborg G; Schønning K; Benfield T
    Antivir Ther; 2009; 14(3):413-22. PubMed ID: 19474475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria.
    van Oosterhout JJ; Brown L; Weigel R; Kumwenda JJ; Mzinganjira D; Saukila N; Mhango B; Hartung T; Phiri S; Hosseinipour MC
    Trop Med Int Health; 2009 Aug; 14(8):856-61. PubMed ID: 19552661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical approach to drug resistance interpretation: expert advice.
    Clotet B; Paredes R
    Curr Opin HIV AIDS; 2007 Mar; 2(2):145-9. PubMed ID: 19372880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral therapy-induced lipid alterations: in-vitro, animal and human studies.
    Mallon PW
    Curr Opin HIV AIDS; 2007 Jul; 2(4):282-92. PubMed ID: 19372900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.